Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations D. Andes, W.A. Craig Clinical Microbiology.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Volume 115, Issue 3, Pages 19S-23S (March 1999)

R. Leclercq Clinical Microbiology and Infection

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Thirty-day mortality of nosocomial systemic bacterial infections according to antibiotic susceptibility in an 800-bed teaching hospital in France D.

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Benchmarking inappropriate empirical antibiotic treatment

J. Gonçalves-Pereira, A. Martins, P. Póvoa

Grepafloxacin: microbiological properties

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

P. Clarke, S. Murchan, E.G. Smyth, H. Humphreys

Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era T.I. Pedersen, M. Howitz, C. Østergaard Clinical.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

In-vitro susceptibility and molecular characterisation of macrolide resistance mechanisms among Streptococcus pneumonia isolates in The Netherlands: the.

Bernard Grenier Clinical Microbiology and Infection

R. Cantón Clinical Microbiology and Infection

Current patterns and evolution of antibiotic resistance among bacterial pathogens involved in acute otitis media Fernando Baquero, Rafael Cantón, Fernando.

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program M.

Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli R.A. Hickman, D. Hughes,

J. Gonçalves-Pereira, A. Martins, P. Póvoa

Serotypes, biotypes and antimicrobial susceptibilities of Haemophilus influenzae isolated from invasive disease in children in Casablanca N. Moustaoui,

D.E. Low Clinical Microbiology and Infection

Impact of antibiotic restrictions: the pharmaceutical perspective

Vector control: a cornerstone in the malaria elimination campaign

Pharmacodynamics of doxycycline

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

G. Höffken Clinical Microbiology and Infection

Effects of gentamicin monotherapy for the initial treatment of community-onset complicated non-obstructive acute pyelonephritis due to Enterobacteriaceae.

Elements of design: the knowledge on which we build

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

J. S. Oxford, S. Bossuyt, S. Balasingam, A. Mann, P. Novelli, R

Decreasing rates of resistance to penicillin, but not erythromycin, in Streptococcus pneumoniae after introduction of a policy to restrict antibiotic.

Levofloxacin in the treatment of ventilator-associated pneumonia

Building in efficacy: developing solutions to combat drug‐resistant S

R. Bitterman, M. Paul, D. Polak, Y. Geffen

Metagenomics and probiotics

B. Sádaba, J.R. Azanza, M.A. Campanero, E. García-Quetglas

N. Maggi-Solcà, C. Valsangiacomo, J.-C. Piffaretti

Ecological effects on the oro- and nasopharyngeal microflora in children after treatment of acute otitis media with cefuroxime axetil or amoxycillin-clavulanate.

W.A. Craig Clinical Microbiology and Infection

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

M. Bassetti, M.P. Molinari, M. Mussap, C. Viscoli, E. Righi

Abstracts cont. Clinical Microbiology and Infection

Benchmarking inappropriate empirical antibiotic treatment

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis S.R. Norrby, J. Quinn, M. Rangaraju,

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

Statin use and clinical outcomes among pneumonia patients

Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin G. Drusano Clinical Microbiology and Infection

Clinical Microbiology and Infection

The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae I. Gustafsson, O. Cars Clinical Microbiology.

W. Eugene Sanders, Christine C. Sanders

Sanford Chodosh Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

M. Biçmen, Z. Gülay, S.V. Ramaswamy, D.M. Musher, D. Gür

In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species† C.B. Moore,

O. Megged, A.M. Yinnon, D. Raveh, B. Rudensky, Y. Schlesinger

Are we losing the fight against malaria one more time?

B.A. Cunha Clinical Microbiology and Infection

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

G. Kahlmeter Clinical Microbiology and Infection

Decision-making in otitis media in children, Part I: epidemiologic data and definitions for a reliable cost-effectiveness analysis Bernard Grenier Clinical.

The future of diagnostic bacteriology

Presentation transcript:

Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations D. Andes, W.A. Craig Clinical Microbiology and Infection Volume 11, Pages 10-17 (January 2005) DOI: 10.1111/j.1469-0691.2005.01265.x Copyright © 2005 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Relationship between pharmacokinetic parameters (Cmax, AUC and time of concentration) in relation to the MIC. Clinical Microbiology and Infection 2005 11, 10-17DOI: (10.1111/j.1469-0691.2005.01265.x) Copyright © 2005 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Left panel: Relationship between β-lactam percentage time above MIC and mortality in a Streptococcus pneumoniae murine infection model. Hollow symbols represent data with cephalosporins. Solid symbols represent data with penicillin. Right panel: Relationship between β-lactam percentage time above MIC and bacteriological eradication in acute otitis media and sinusitis. Hollow circles represent data with Haemophilus influenzae in otitis media. Hollow squares represent data with H. influenzae in sinsusitis. Solid circles represent data with penicillin-susceptible S. pneumoniae in otitis media. Solid squares represent data with penicillin-susceptible S. pneumoniae in sinusitis. Grey circles represent data with penicillin-intermediate and -resistant S. pneumoniae in otitis media. Clinical Microbiology and Infection 2005 11, 10-17DOI: (10.1111/j.1469-0691.2005.01265.x) Copyright © 2005 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 3 Relationship between cephalosporin percentage time above MIC and microbiological efficacy against Enterobacteriaciae in a murine thigh infection model. Hollow symbols represent data with ESBL-producing organisms. Solid symbols represents data with non-ESBL-producing organisms. The dashed horizontal line represents the burden of organisms at the start of therapy. The vertical dashed line represent the %T > MIC target associated with a net static effect. Clinical Microbiology and Infection 2005 11, 10-17DOI: (10.1111/j.1469-0691.2005.01265.x) Copyright © 2005 European Society of Clinical Infectious Diseases Terms and Conditions